Descovy (emtricitabine/tenofovir alafenamide) / Gilead - LARVOL DELTA

A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trial. (PubMed, J Acquir Immune Defic Syndr) - "Despite similar HIV incidence rates, the non-inferiority of F/TAF was not demonstrated, probably due to low statistical power primarily driven by low adherence. However, there is compelling evidence from multiple studies supporting the efficacy of F/TAF as PrEP regardless of sex."

Head-to-Head • Journal • Human Immunodeficiency Virus • Infectious Disease

CARE: Comprehensive Assessment of Real-world Effectiveness of F/TAF in Persons Who Use Drugs (PWUD) (clinicaltrials.gov) - P=N/A | N=200 | Not yet recruiting | Sponsor: Heather Henderson

New trial • Real-world evidence

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: University of Texas Southwestern Medical Center | Active, not recruiting ➔ Completed | Trial completion date: Aug 2026 ➔ Dec 2025 | Trial primary completion date: Dec 2025 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Atherosclerosis • Cardiovascular • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

DD-PrEP:: Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Johns Hopkins University

New P1 trial • Human Immunodeficiency Virus • Infectious Disease

Longitudinal analysis of metabolic changes in people with HIV on integrase inhibitor-based versus efavirenz-based therapy: a prospective real-world cohort study in China. (PubMed, BMC Infect Dis) - "INSTI-based ART was associated with sustained weight gain but did not worsen long-term dyslipidemia compared to an EFV-based regimen in a real-world setting. Hepatic steatosis correlated with metabolic parameters rather than INSTI exposure."

Journal • Real-world evidence • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

Switch to BIC/TAF/FTC or DTG + TDF/FTC in virologically suppressed PWH: outcomes in real-world setting with and without tenofovir resistance. (PubMed, Clin Infect Dis) - P | "in a real-world setting, switching to BIC/TAF/FTC or DTG + TDF/FTC in PWH with virological success was associated with a non-significant risk of VF, but M184V or M184I mutations and tenofovir resistance had no effect on VF. Most VF were blips or related to unmeasured adherence issues."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

PURPOSE 2: Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (clinicaltrials.gov) - P3 | N=3292 | Active, not recruiting | Sponsor: Gilead Sciences | Trial completion date: May 2028 ➔ Aug 2028

Trial completion date • Human Immunodeficiency Virus • Infectious Disease

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) (clinicaltrials.gov) - P2 | N=550 | Not yet recruiting | Sponsor: ViiV Healthcare | Trial completion date: Mar 2029 ➔ Nov 2028

Trial completion date • Human Immunodeficiency Virus • Infectious Disease

Viral Tug-of-War: Incomplete Hepatitis B Suppression Despite Tenofovir Alafenamide-Emtricitabine Therapy in Human Immunodeficiency Virus and Hepatitis B Co-Infection (ASHP 2025) - No abstract available

Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Pilot outcomes of a telehealth model for youth PrEP (TelePrEP) among youth at risk for HIV in Colorado. (PubMed, HIV Res Clin Pract) - "Youths 14-24 years of age eligible for PrEP using oral tenofovir alafenamide and emtricitabine (F/TAF) were enrolled in a prospective type 1 hybrid effectiveness implementation study...PrEP uptake and retention remain challenging for youth at risk for HIV. Further tailoring of PrEP models of care is needed to achieve risk reduction goals for youth."

Journal • Human Immunodeficiency Virus • Infectious Disease

Bictegravir's effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study. (PubMed, Int J STD AIDS) - "A significant gradual elevation of CD4/CD8 ratio was also observed (0.51 ± 0.30 before switch vs 0.69 ± 0.35 at 12 months, p < 0.001).ConclusionThe results of the present study indicate that BIC/TAF/FTC may improve the immunological response and reduce the proportion of PWHIV experiencing persistent LLV. Further studies in larger patient series are needed to determine the full beneficial role of bictegravir."

Journal • Observational data • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

Preexposure Prophylaxis Prescription Dispensation Status and HIV-1 Acquisition. (PubMed, JAMA Netw Open) - "Retrospective observational cohort study from January 2021 to December 2023 using US pharmacy claims data from HIV-1-negative adults who received daily oral brand emtricitabine and tenofovir disoproxil fumarate (F/TDF), generic F/TDF (gF/TDF), or emtricitabine and tenofovir alafenamide fumarate (F/TAF), or intramuscular injection of cabotegravir every 2 months, for PrEP (after a 180-day washout period for previous PrEP use). In this cohort study, HIV-1 incidence was higher in individuals with abandoned or rejected PrEP claims compared with those with dispensed claims. These findings highlight the importance of targeted strategies to improve PrEP claim dispensation and remove payer barriers to reduce HIV-1 transmission."

Journal • Observational data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Authors' Reply to Letter to the Editor Regarding 'Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study'. (PubMed, HIV Med) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease

Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV-Infected Individuals in Southwest China: A Retrospective Observation Study. (PubMed, Immun Inflamm Dis) - "For elderly HIV/AIDS patients, B/F/TAF is a safe option to achieve and maintain virological suppression and immune recovery. In terms of lipid metabolism, the metabolic effects of BIC/FTC/TAF in the treated patients are not significant, and the effects in untreated patients require longer follow-up."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • CD4 • CD8

Diagnosis of HIV infection during pregnancy: Trends from a national cohort in Spain. (PubMed, HIV Med) - "Among women diagnosed with HIV during pregnancy, half were late presenters, and one-third were diagnosed after the first trimester, with higher percentages among African and Latin American women. There was a high proportion of caesarean deliveries. Most women initiated ART promptly after cohort enrolment and achieved undetectable VL at the end of pregnancy."

Journal • Human Immunodeficiency Virus • Infectious Disease

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. (PubMed, Sci Rep) - "Daily oral pre-exposure prophylaxis (PrEP), including emtricitabine/tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir alafenamide fumarate (TAF), is a key strategy for HIV prevention. TAF-only (β = 2.532, 95%CI 0.708-4.356) and TDF-TAF (β = 2.756, 95%CI 0.890-4.621) were associated with significantly increased weight gain compared to TDF-only use. Closer monitoring of weight gain is recommended for individuals using TAF to prevent HIV."

Journal • Human Immunodeficiency Virus • Infectious Disease

EXPRESS-PrEP: Evaluating PrEP Rapid Engagement and Same-Day Start for HIV Prevention in gbMSM. (PubMed, Int J Infect Dis) - "Same-day PrEP initiation is safe, feasible, and improves uptake and persistence. Adoption of this model may reduce barriers and accelerate HIV prevention."

Journal • Human Immunodeficiency Virus • Infectious Disease

An Old Problem With a Re-purposed Solution: Novel Application of Emtricitabine-Tenofovir to Treat Persistent HBV Viremia (ACG 2025) - "Importantly, HBV DNA levels were consistently elevated with other NUC therapies across all cases, then became undetectable shortly after initiation of either FTC-TDF or FTC-TAF. Abbreviations: EMR (electronic medical records); ETV (Entecavir); FTC-TAF (Emtricitabine-Tenofovir Alafenamide); FTC-TDF (Emtricitabine-Tenofovir Disoproxil Fumarate); IU/mL (international units per milliliter); LDT (Telbivudine); LMV (Lamivudine); NUC (Nucleos(t)ide Analogues).​"

Fibrosis • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Liver Cirrhosis • Solid Tumor

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. (PubMed, J Infect Dis) - "Acquisition of HIV while receiving LEN and resistance to LEN in the context of unrecognized HIV was rare but associated with the emergence of the N74D LEN resistance-associated substitution in this population."

Journal • Human Immunodeficiency Virus • Infectious Disease

Antiviral efficacy of doravirine-based regimens in patients with NNRTI resistance in Europe: a retrospective observational study (EACS 2025) - "Most received DOR with TDF/3TC (91.4%); 8.6% received DOR with TAF/FTC. One experienced patient (1.8%) with multiple baseline NRTI and NNRTI RAMs that collectively may impact sensitivity to DOR experienced virological failure. Conclusions : In this well-characterised multicentre European cohort of PLWH with NNRTI RAMs and preserved genotypic DOR susceptibility, DOR-based regimens achieved high virological success and excellent treatment retention at 48 weeks."

Late-breaking abstract • Observational data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Metabolic and Body Composition Outcomes at 48 Weeks among People with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide Switching to Doravirine with or without Tenofovir Disoproxil Fumarate: ACTG A5391 (the DO-IT Trial) (EACS 2025) - "Changes at 48 weeks in triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and HOMA-IR were not different between DOR+TAF/FTC or DOR+TDF/FTC versus INSTI+TAF/FTC ( Figure ). Conclusions : Among PWH with obesity and insulin resistance, switching from an INSTI+TAF regimen to regimens containing DOR with either TAF or TDF did not meaningfully alter lipids, HOMA-IR, or body composition at 48 weeks. Other interventions are needed to improve metabolic health or reduce adiposity in people who have gained excessive weight or are obese following ART initiation."

Human Immunodeficiency Virus • Infectious Disease

Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO Study) (EACS 2025) - "Conclusions : Switching to BIC/FTC/TAF avoided 19.9% of potential interactions while maintaining efficacy and safety. These findings may help optimize clinical management in this high-risk population."

Clinical • Observational data • Human Immunodeficiency Virus • Infectious Disease

Interaction between GLP-1 receptor agonists and cART in PLWH and obesity: a case report (EACS 2025) - "Newer regimens, particularly those containing second-generation integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF), have been associated with significant weight gain, while tenofovir disoproxil fumarate (TDF) appears to have a weight-suppressive effect.We describe a 62-year-old man living with HIV on a stable ART regimen (TAF/FTC/DRV/c), with a history of hypertensive heart disease and class II obesity (BMI 35 kg/m2). This case highlights the potential of GLP-1 receptor agonists as an effective treatment option for obesity in PLWH, particularly when lifestyle modifications have failed. Further studies are warranted to explore their long-term safety and efficacy in this population, and to better characterize any pharmacological interactions with antiretroviral therapy."

Case report • Clinical • Human Immunodeficiency Virus • Infectious Disease

Advanced coronary artery disease in a low-risk HIV patient – a case for early statin intervention (EACS 2025) - "His antiretroviral regimen initially was Kivexa and Efavirenz, which was then switched to Atripla in 2020 and switched to Descovy and Efavirenz in 2022. This case reinforces the inadequacy of relying solely on traditional risk scores for cardiovascular risk assessment in People Living With HIV(PLWH). Chronic inflammation and endothelial dysfunction associated with HIV infection may drive atherosclerosis independently of classical risk factors. In alignment with the REPRIEVE study outcomes, the BHIVA now recommends initiating statins in PLWH based on Q-Risk, advocating for early, primary preventive cardiovascular management in this population."

Clinical • Metastases • Human Immunodeficiency Virus • Infectious Disease • CD4

A case of disseminated Trichosporon asahii infection in a patient with advanced human immunodeficiency virus disease and Kaposi sarcoma (EACS 2025) - "Treatment with DRV/c/FTC/TAF was initiated and, following Kaposi sarcoma diagnosis with no response to initial treatment, paclitaxel chemotherapy...Despite antifungal treatment with voriconazole and amphotericin B, the patient developed septic shock and worsening respiratory failure, requiring ICU admission and mechanical ventilation...The combination of severe CD4 depletion, ongoing corticosteroid exposure, and mucosal barrier injury from chemotherapy likely predisposed to invasive fungal disease. Early clinical suspicion, timely mycologic confirmation, and aggressive supportive care are critical in the management of such high-risk patients."

Clinical • Metastases • Human Immunodeficiency Virus • Infectious Disease • Septic Shock • CD4